DUBLIN, Nov. 26, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Immune Checkpoint Inhibitors Market, 2014 - 2024" report to their offering.
http://photos.prnewswire.com/prnh/20130307/600769
Cancer is known to be one of the leading causes of death worldwide. The field of oncology is vast and comprises several indications, including some rare / orphan forms. Although oncology continues to be one of the most active areas in terms of drug development, there is still a significant unmet need.
The focus of drug developers is gradually moving towards immunotherapeutics, which make use of the body's own immune system or its components to fight cancer. It is a relatively new concept, with the only success being targeted antibody based therapeutics (including monoclonal and conjugated antibodies). There has been a surge of interest in other classes of immunotherapeutics to manage and treat cancer, including Immune Checkpoint Inhibitors, therapeutic cancer vaccines and other whole cell based therapies.
Immune checkpoints are molecules that regulate (stimulate or inactivate) the immune cells. Yervoy (an anti CTLA-4 drug), the foremost drug to be launched in this domain, is currently being mirrored by various other drugs such as Opdivo, Keytruda (both anti PD-1 drugs) and several others under clinical development. The market, with an opportunistic development pipeline, caters to the participation of various market players (big and small) over a common platform. With an ongoing rush to emerge as leaders in the evolving market, various stakeholders have collaborated to establish their foothold in a relatively short time period.
Specifically, we expect Yervoy, Opdivo and Keytruda to achieve blockbuster status in the near future. The anticipated success of Immune Checkpoint Inhibitors shall prove to be a harbinger for emerging players and a strong impetus to the development pace of the other pharmaceutical giants.
Key Topics Covered:
1. Preface
2. Executive Summary
3. Cancer Therapeutics and Immuno-Oncology
4. Current Market Landscape
5. CTLA-4 Inhibitors: Key Molecules and Future Outlook
6. PD-1 and PD-L1 Inhibitors: Key Molecules and Future Outlook
7. Novel Immune Checkpoint Inhibitors: Key Molecules and Future Outlook
8. Competition in Key Indication Areas
9. Deals and Partnerships
10. Company Profiles
11. Conclusion
12. Appendix 1: Tabulated Data
13. Appendix 2: List of Companies and Organizations
Companies Mentioned:
- 4-Antibody AG
- AbbVie
- Abbott
- Adimab
- Advaxis
- Agenus
- AgonOX
- Ambrx
- American Society of Clinical Oncology
- Amgen
- Amplimmune
- AnaptysBio
- Aurigene
- Azienda Ospedaliera Universitaria Senese
- Bayer
- BeiGene
- Bio-Matrix Scientific Group
- BioWa
- Boehringer Ingelheim
- Bristol Myers Squibb
- Celgene
- Cell Genesys
- Celldex Therapeutics
- Clinical Research Institute
- CoStim Pharmaceuticals
- Compugen
- CureTech
- Eddingpharm
- Facet Biotech
- Five Prime Therapeutics
- GITR /Tolerx
- Georgia Health Sciences University
- Gilead BioSciences
- GlaxoSmithKline
- Gustave Roussy Institute
- HealthCare Ventures
- IDM
- Immutep
- Incyte Corporation
- Innate Pharma
- KAHR Medical
- Kyowa Hakko Kirin
- Lankenau Institute for Medical Research (LIMR)
- Laureate Pharma
- Lee's Pharma
- Lonza Biologics
- Ludwig Cancer Research
- MRC Technology
- MacroGenics
- Masonic Cancer Center
- MedImmune/AstraZeneca
- Medarex
- Medivation
- Merck
- Merck Serono
- Millennium Pharmaceuticals
- MolMed S.p.A
- MorphoSys
- NewLink Genetics
- Novartis
- Novo Nordisk
- Oncothyreon
- Ono Pharmaceutical
- Onyx (subsidiary of Amgen)
- Orega Biotech
- PDL Biopharma
- Pfizer
- Pierre Fabre
- Prima BioMed
- Recipharm Cobra Biologics
- Regis Technologies
- Roche/Genentech
- Samsung Biologics
- Seattle Genetics
- Servier
- Sorrento Therapeutics
- Spring Bioscience
- Tesaro
- ToleroTech
- University of California, Berkeley
- University of Iowa Pharmaceutical Services
- University of Minnesota
- University of Texas
- Ventana Medical Systems
- arGEN-X
- iTeos Therapeutics
For more information visit http://www.researchandmarkets.com/research/gbhpdt/immune_checkpoint
Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/immune-checkpoint-inhibitors-market-2014-2024-300001569.html
SOURCE Research and Markets
